<DOC>
	<DOCNO>NCT01581476</DOCNO>
	<brief_summary>The purpose study determine whether use blood pressure lower drug , Angiotensin convert enzyme inhibitor ( ACEIs ) blood fat ( lipid ) lower drug ( statin ) may place treatment adolescent diabetes help reduce serious long-term health problem population .</brief_summary>
	<brief_title>Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<mesh_term>Quinapril</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>1 . Age 10 16 year . 2 . T1D diagnose 1 year Cpeptide negative . 3 . Centralised assessment ACR base six early morning urine deem upper tertile risk adjustment age , gender , age diagnosis duration disease . 1 . Non T1D , i.e . type 2 diabetes , insulin dependent diabetes relate monogenic disease , secondary diabetes . 2 . ACR base six early morning urine deem low risk subsequent development CVD DN . 3 . Pregnancy unwillingness comply contraceptive advice regular pregnancy test throughout trial . 4 . Breast feed 5 . Severe hyperlipidaemia family history data support diagnosis familial hypercholesterolaemia . 6 . Established hypertension unrelated DN . 7 . Prior exposure investigational product , statin ACEI . 8 . Unwillingness/inability comply study protocol . 9 . Other comorbidities consider unsuitable investigator ( exclude treat hypothyroidism coeliac disease ) . 10 . Proliferative retinopathy . 11 . Renal disease associate Type 1 Diabetes .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Adolescence</keyword>
</DOC>